Tailored to fit our multi-profile audience, the MedFIT conference programme features latest opinions on trending topics related to collaborative innovation partnerships and will focus on market access, financing, the digitalisation of the sector and regulations.

We invite you to discover a preliminary conference programme organised around two plenary sessions and four tracks:

26 Jun 2018 10:30 am

The medtech industry is undergoing many changes: New regulations, evolution from product-based to value-based healthcare, digitalisation, AI integration… All these transformations are going to have a significant impact on companies, from start-ups to big players, all of whom will need to adapt in order to innovate and keep or increase their market shares. Of course, there will be hurdles to overcome – but it’s also a great opportunity for innovation.

In this plenary session, our high-level visionary panelists will discuss what will be driving growth in the sector over the next decade, as well as the ways that medtech players can turn these challenges into opportunities for growth.

#FutureGrowth&Innovation #Digital #Regulations

The speakers

  • Mirren Mandalia
    J&J London Innovation Center

  • Sacha Loiseau
    MAUNA KEA TECHNOLOGIES

  • Zishan Haroon
    Julz Co LLC

I want to become a Speaker of this session

27 Jun 2018 2:00 pm

To facilitate market access and be able to offer products that comply with regulations and local healthcare authorities requirements, the medtech industry needs to move away from a product-based strategy and towards a value-based one. Of course, innovation itself is still crucial, but nowadays medtech players also have to take cost-containment effectiveness, quality, and access to care into account: they need to focus on better health outcomes for patients or end users in order to remain competitive.

Our panelists will talk about how they are taking all these aspects into account in order to foster growth and innovation, as well what strategies you can apply to help you stay on top.

#ValueBasedHealthcare #Innovation #MarketAccess

The speakers

  • Anne Osdoit
    Venture Consultant, Sofinnova Partners

  • Kayar Raghavan
    LONDON BUSINESS ANGELS

  • Olivier Delporte
    Miracor Medical Systems

  • Raquel Riera
    BIOCAT

I want to become a Speaker of this session

Collaboration is key to advancing innovation from bench to market and the type of partnership vary depending on the innovation’s stage of development. In light of recent changes of the medtech sector which trends can be highlighted in the set up and management of collaboration at both early and late-stages?

26 Jun 2018 3:00 pm

Academic and clinical research in medical technologies is not just about publications and presentations. It is also about being able to bring an idea from its inception to its patenting and ultimately into functioning, new, cutting-edge medical technologies with commercial and clinical applications. Still, translating academic research into commercial results that benefit patients can be a long road that is fraught with pitfalls.

We’ll hear concrete examples and discuss the hurdles one encounters when financing research projects and developing technologies before spinning out, licensing out, or setting up and managing public-private collaborations. Our panel of experts will address all these crucial issues and outline the improvements that could be made to accelerate the transfer of technology from the research to the market stage.

#PublicPrivateCollaborations #SpinOut #Licensing

The speakers

  • Bruno Cocheteux
    Sibaya - BCPharMed

  • Markus Clemenz
    Verapido Medical

  • Mathilde Desselle
    Queensland University of Technology

  • Nihal Engin Vrana
    Protip

  • Tamar Raz
    Hadasit

I want to become a Speaker of this session

26 Jun 2018 9:00 am

Innovative start-ups often see large corporations as the partners that could best help their businesses mature and grow. Conversely, large corporations are seeking new sources of innovation. The solution: Working together!

Many partnerships should be setup, such as: License agreements, co-marketing, co-development, joint ventures… Of course, implementing a successful collaboration is not so straightforward. How it should be set up depends not only on the start-up’s stage of maturity, but also on each partner’s expectations.

Our panels of experts will discuss the different collaboration patterns and explore the following questions: What criteria should inform the decision? How will these impact the start-up’s development? How does that affect fundraising?

#Startups&SMEs #BigPlayers #Collaboration

The speakers

  • Rogier Receveur
    Medtronic

  • Rob Lips
    GATT Technologies BV

  • Benno Lansdorp
    DEMCON Medical Robotics

I want to become a Speaker of this session

In a constantly changing financial environment, medtech companies face many challenges in seeking funding for their development. Looking from 2 different points of view (of entrepreneurs on one side and investors on the other) the discussions will try to provide an insight on the financial landscape and give some hints on how to approach investors.

26 Jun 2018 2:00 pm

When it comes to funding a medtech start-up, there are many ways that you can go about it. Even though VCs are often the main source of funding for companies raising large amounts of capital, there are also other funding options available: Soft money and foundations, business angels and family offices, crowdfunding… Each has its own set of advantages and drawbacks and choosing the right investment for your company is not an easy thing to do.

Because it is essential to be knowledgeable about all these options and to weigh the pros and cons, successful CEOs will be sharing their experience and the choices they made for financing their start-up, providing valuable advice to young entrepreneurs.

#Tips&Tricks #Startups #EarlyStageInvestment

The speakers

  • Assaf Dekel
    Orthospace

  • Kadem Al-Lamee
    ARTERIUS Limited

I want to become a Speaker of this session

27 Jun 2018 3:00 pm

Recently, investors have become incredibly risk adverse in the medtech industry and they hardly invest without actual clinical trial data. Moreover, not all investors have the same assessment criteria or the same expectations.

This situation is challenging for start-ups and makes it harder to find the right partner to raise equity capital with in the new medtech era. In this session, our panelists will discuss the different approaches investors from Europe and abroad have for funding innovative start-ups, how to get their attention, and what a start-up should do to meet their expectations.

#EarlyStageFinancing #EquityInvestment #InvestorsExpectations

The speakers

  • Anke Caßing
    Hightechgrunderfonds

  • Anne E. Sissel
    Baxter Ventures

  • Daniel Lyle
    Debere Capital Partners

  • Thijs Cohen Tervaert
    Inkef Capital

I want to become a Speaker of this session

One country, one set of rules. When deciding to access a market or complying with new regulations, the job proves to be sometimes difficult for medtech companies and a clear strategy must be put in place. The discussions in this track will focus on the advantages and disadvantages of established vs emerging markets and the impact on innovation of complying with new regulations.

26 Jun 2018 4:30 pm

Co-organised with:       PART 1: ACCESSING CANADIAN MARKET: MEET THE KEY PLAYERS

Each country has its own set of rules. Accessing different markets means adapting your strategy to comply with completely different processes and requirements. The main factors resulting in varieties in market access are: the process of getting reimbursed for product use, the DRG systems’ support of or the resistance to adopting new technologies, and the complexity and duration of the licensing and regulatory tracks.

These workshops will focus on how to adapt your strategy to the target market, how to overcome hurdles, and offer advice on how best to comply with the country’s regulations and licensing and reimbursement processes. It will also be an opportunity to meet key local stakeholders and understand local medtech ecosystems.

#MarketAccess #ClinicalTrialsStrategy  

The speakers

  • Eric Filion
    LOK NORTH AMERICA

I want to become a Speaker of this session

27 Jun 2018 9:00 am

Co-organised with:       PART 2: NAVIGATING THROUGH THE EUROPEAN AND THE ISRAELI MARKETS

Each country has its own set of rules. Accessing different markets means adapting your strategy to comply with completely different processes and requirements. The main factors resulting in varieties in market access are: the process of getting reimbursed for product use, the DRG systems’ support of or the resistance to adopting new technologies, and the complexity and duration of the licensing and regulatory tracks.

These workshops will focus on how to adapt your strategy to the target market, how to overcome hurdles, and offer advice on how best to comply with the country’s regulations and licensing and reimbursement processes. It will also be an opportunity to meet key local stakeholders and understand local medtech ecosystems.

#MarketAccess #ClinicalTrialsStrategy

I want to become a Speaker of this session

27 Jun 2018 9:00 am

Designed to strengthen existing data protection, the GDPR has a significant impact, placing new obligations on medtech businesses as far as handling highly sensitive patient information is concerned. In fact, the GDPR states that collecting data from and for clinical trials increases the risk of the freedoms and rights of natural persons being infringed upon.

Since medtech companies require extensive preparation to adjust their data protection to new standards, and considering the mandatory nature of those standards as well as the looming penalties imposed on non-compliant businesses, how will the implementation of the new regulations affect innovation in medtech?

#GDPR&DataProtection #NewRegulations #Compliance #Innovation

The speakers

  • Cécile Théard-Jallu
    De Gaulle, Fleurance & Associés

  • Artur Steffen
    GoClinic

  • Xavier Gobert
    My Data Trust

I want to become a Speaker of this session

At present digitalization and AI are more and more present in our lives and the healthcare sector is no exception. The question is no longer if but when they will be fully integrated in care delivery and will it be perceived more as an evolution of the sector or as a complete revolution? This 4th track will highlight the impact AI and digital integration have on medtech companies, their existing as well as future products and will discuss what impact these changes will have on innovation.

26 Jun 2018 2:00 pm

There is no doubt that in the near future, AI will affect the whole healthcare system, as well as care delivery. Incorporating AI into medtech and diagnostics innovations will allow companies to provide personalized care for individuals, from their initial diagnosis to ongoing treatment options. This will empower patients, allow companies to improve their devices over time, and enable them to refine their algorithms as they amass more data. What’s more, new cross-industry collaborations, combining different resources and areas of expertise, will enable the creation of innovative solutions that wil improve patient care on a global scale.

How will these next level changes affect medtech innovations? How will they be incorporated into existing technologies? Will they be perceived as a revolution or merely as an expected industry development?

#AIintegration #Medtech(r)Evolution #NewCollaborations

The speakers

  • Didier Patry
    France Brevets

  • François Lescure
    MedecinDirect

  • Luc Soler
    IRCAD

I want to become a Speaker of this session

27 Jun 2018 4:30 pm

As the industry moves towards a value-based healthcare model, digitalisation will reshape the medtech landscape like it has never been before. Bolstered by new opportunities, emerging threats, and disruptive forces, medtech companies need to develop a clear strategy to keep their business models relevant and competitive.

Since digitalisation is no longer a goal but an ongoing journey, what are the keys to getting digital transformation right in medtech from a business point of view? Which strategy is best: Adapting existing business models, inventing new ones, or both? How will new digital solutions be approved, priced, and marketed?

#DigitalTransformation #BusinessModels #Pricing&MarketAccess

The speakers

  • Christian Hense
    UNIVERSAL DX

  • Clément Destoumieux
    MEDMESAFE

  • Paul Timmers
    University of Oxford

  • Thierry Laugel
    KURMA PARTNERS

I want to become a Speaker of this session